...
首页> 外文期刊>Journal of pharmaceutical investigation >Design and evaluation of esmolol hydrochloride ocular inserts with special reference to glaucoma treatment
【24h】

Design and evaluation of esmolol hydrochloride ocular inserts with special reference to glaucoma treatment

机译:青光眼治疗特别参考盐酸盐盐麦醇眼嵌剂的设计与评价

获取原文
获取原文并翻译 | 示例

摘要

In developing a drug delivery strategy, issues of absorption, distribution, metabolism, and elimination must be considered. The eye presents unique opportunities and challenges when it comes to the delivery of pharma-ceuticals. While absorption by this route is bungling, there are few side effects with conventional ocular dosage forms. Hence, ocular inserts were prepared with prolonged release of drug and minimum swelling within cul-de-sac using esmolol HC1 drug the work focuses on treatment of glaucoma by formulating ocular inserts. By using different polymeric combination of esmolol HC1 using hydroxy-propyl methyl cellulose (HPMC 3-5 %), chitosan (3-5 %), polyvinyl alcohol (PVA 3-5 %), methyl cellulose (3-5 %) as polymer by solvent casting technique with objective of increasing contact time, achieving controlled release, reduction on frequency of administration and greater therapeutic efficiency. The prepared ocular insert were then evaluated for physical appearances tensile strength, % elongation at break, stress, weight variation, uniformity of thickness, % moisture absorption, surface pH, folding endurance, Fourier transform infrared spectroscopy, in-vitro transcorneal permeation studies etc. It is evident from these study that formed polymeric ocular insert have appreciable strength and safety. Physicochemical characterization and in vitro transcorneal permeation studies revels that, the prepared ocular insert formulation F2 and F8 containing HPMC and PVA had release their drug content, 98.54 and 97.24 respectively over a extended period of 24 h. Hence these formulation selected as best optimized formulation.
机译:在制定药物输送策略时,必须考虑吸收,分布,新陈代谢和消除问题。当涉及发货的药水时,眼睛呈现出独特的机会和挑战。虽然这条路线的吸收凸起,但常规眼睛剂型副作用很少。因此,使用ESMOLOL HC1药物延长释放药物和CUL-DE-SAC中的药物和最小溶胀的眼部插入物,该工作侧重于通过配制眼刀片来治疗青光眼。通过使用羟基丙基甲基纤维素(HPMC 3-5%),壳聚糖(3-5%),聚乙烯醇(PVA 3-5%),甲基纤维素(3-5%)作为聚合物的不同聚合物组合通过溶剂铸造技术的目的是增加接触时间,实现控制释放,减少给药频率和更高的治疗效率。然后评估制备的眼部插入物,用于物理出场拉伸强度,断裂,应力,重量变异,厚度均匀,厚度均匀,表面pH,折叠耐久性,傅里叶变换红外光谱,体外转化红外光谱,体外转化红外光谱,体外转化红外光谱,体外转换,体外转换,体外转化,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转换,体外转化率,体外转换,所述异常转换型渗透性研究等。从这些研究中显而易见的是,形成的聚合物眼部插入物具有明显的强度和安全性。物理化学表征和体外转基因渗透研究陶醉的研究陶醉于其中,含有HPMC和PVA的制备的眼部插入物配方F2和F8分别在24小时的延长时段分别释放出其药物含量98.54和97.24。因此,这些配方选择了最佳优化的制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号